Faculty of Medicine, MV Lomonosov Moscow State University, 119991, Moscow, Russia.
Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet, Box 210, Stockholm, SE-171 77, Sweden.
Cell Death Dis. 2018 Jan 25;9(2):117. doi: 10.1038/s41419-017-0063-y.
The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of all lung cancer cases. In spite of achievements in understanding the pathogenesis of this disease and the development of new approaches in its treatment, unfortunately, lung ADC is still one of the most aggressive and rapidly fatal tumor types with overall survival less than 5 years. Lung ADC is often diagnosed at advanced stages involving disseminated metastatic tumors. This is particularly important for the successful development of new approaches in cancer therapy. The high resistance of lung ADC to conventional radiotherapies and chemotherapies represents a major challenge for treatment effectiveness. Here we discuss recent advances in understanding the molecular pathways driving tumor progression and related targeted therapies in lung ADCs. In addition, the cell death mechanisms induced by different treatment strategies and their contribution to therapy resistance are analyzed. The focus is on approaches to overcoming drug resistance in order to improve future treatment decisions.
最常见的肺癌类型是腺癌（ADC），约占所有肺癌病例的 40%。尽管在了解这种疾病的发病机制和开发新的治疗方法方面取得了成就，但不幸的是，肺 ADC 仍然是最具侵袭性和快速致命的肿瘤类型之一，总生存率不到 5 年。肺 ADC 通常在涉及播散性转移瘤的晚期诊断。这对于癌症治疗新方法的成功开发尤为重要。肺 ADC 对常规放射治疗和化学疗法的高度耐药性代表了治疗效果的主要挑战。在这里，我们讨论了在理解驱动肿瘤进展的分子途径以及相关的肺 ADC 靶向治疗方面的最新进展。此外，还分析了不同治疗策略诱导的细胞死亡机制及其对治疗耐药性的贡献。重点是克服药物耐药性的方法，以改善未来的治疗决策。
